Signia Therapeutics

Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently, and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options. Signia Therapeutics proposes a breakthrough strategy for the development of a new generation of antivirals that will target the infected host-cell rather than the virus.